These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1084 related articles for article (PubMed ID: 29174803)

  • 1. HBXIP-elevated methyltransferase METTL3 promotes the progression of breast cancer via inhibiting tumor suppressor let-7g.
    Cai X; Wang X; Cao C; Gao Y; Zhang S; Yang Z; Liu Y; Zhang X; Zhang W; Ye L
    Cancer Lett; 2018 Feb; 415():11-19. PubMed ID: 29174803
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HBXIP drives metabolic reprogramming in hepatocellular carcinoma cells via METTL3-mediated m6A modification of HIF-1α.
    Yang N; Wang T; Li Q; Han F; Wang Z; Zhu R; Zhou J
    J Cell Physiol; 2021 May; 236(5):3863-3880. PubMed ID: 33305825
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HBXIP promotes gastric cancer
    Yang Z; Jiang X; Li D; Jiang X
    Aging (Albany NY); 2020 Oct; 12(24):24967-24982. PubMed ID: 33048840
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The oncoprotein HBXIP enhances angiogenesis and growth of breast cancer through modulating FGF8 and VEGF.
    Liu F; You X; Wang Y; Liu Q; Liu Y; Zhang S; Chen L; Zhang X; Ye L
    Carcinogenesis; 2014 May; 35(5):1144-53. PubMed ID: 24464787
    [TBL] [Abstract][Full Text] [Related]  

  • 5. miR-520b regulates migration of breast cancer cells by targeting hepatitis B X-interacting protein and interleukin-8.
    Hu N; Zhang J; Cui W; Kong G; Zhang S; Yue L; Bai X; Zhang Z; Zhang W; Zhang X; Ye L
    J Biol Chem; 2011 Apr; 286(15):13714-22. PubMed ID: 21343296
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The oncoprotein HBXIP modulates the feedback loop of MDM2/p53 to enhance the growth of breast cancer.
    Li H; Liu Q; Wang Z; Fang R; Shen Y; Cai X; Gao Y; Li Y; Zhang X; Ye L
    J Biol Chem; 2015 Sep; 290(37):22649-61. PubMed ID: 26229107
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The oncoprotein HBXIP suppresses gluconeogenesis through modulating PCK1 to enhance the growth of hepatoma cells.
    Shi H; Fang R; Li Y; Li L; Zhang W; Wang H; Chen F; Zhang S; Zhang X; Ye L
    Cancer Lett; 2016 Nov; 382(2):147-156. PubMed ID: 27609066
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The oncoprotein HBXIP promotes human breast cancer growth through down-regulating p53 via miR-18b/MDM2 and pAKT/MDM2 pathways.
    Li H; Wang Z; Jiang M; Fang RP; Shi H; Shen Y; Cai XL; Liu Q; Ye K; Fan SJ; Zhang WY; Ye LH
    Acta Pharmacol Sin; 2018 Nov; 39(11):1787-1796. PubMed ID: 30181579
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MiR-145-targeted HBXIP modulates human breast cancer cell proliferation.
    Jiang Y; Wang D; Ren H; Shi Y; Gao Y
    Thorac Cancer; 2019 Jan; 10(1):71-77. PubMed ID: 30381907
    [TBL] [Abstract][Full Text] [Related]  

  • 10. N6-methyladenosine METTL3 promotes the breast cancer progression via targeting Bcl-2.
    Wang H; Xu B; Shi J
    Gene; 2020 Jan; 722():144076. PubMed ID: 31454538
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oncoprotein HBXIP Modulates Abnormal Lipid Metabolism and Growth of Breast Cancer Cells by Activating the LXRs/SREBP-1c/FAS Signaling Cascade.
    Zhao Y; Li H; Zhang Y; Li L; Fang R; Li Y; Liu Q; Zhang W; Qiu L; Liu F; Zhang X; Ye L
    Cancer Res; 2016 Aug; 76(16):4696-707. PubMed ID: 26980761
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The oncoprotein HBXIP promotes glucose metabolism reprogramming via downregulating SCO2 and PDHA1 in breast cancer.
    Liu F; Zhang W; You X; Liu Y; Li Y; Wang Z; Wang Y; Zhang X; Ye L
    Oncotarget; 2015 Sep; 6(29):27199-213. PubMed ID: 26309161
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Displacement of Bax by BMF Mediates STARD13 3'UTR-Induced Breast Cancer Cells Apoptosis in an miRNA-Depedent Manner.
    Guo X; Xiang C; Zhang Z; Zhang F; Xi T; Zheng L
    Mol Pharm; 2018 Jan; 15(1):63-71. PubMed ID: 29179557
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BAG3-mediated miRNA let-7g and let-7i inhibit proliferation and enhance apoptosis of human esophageal carcinoma cells by targeting the drug transporter ABCC10.
    Wu K; Yang Y; Zhao J; Zhao S
    Cancer Lett; 2016 Feb; 371(1):125-33. PubMed ID: 26655271
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The oncoprotein HBXIP uses two pathways to up-regulate S100A4 in promotion of growth and migration of breast cancer cells.
    Liu S; Li L; Zhang Y; Zhang Y; Zhao Y; You X; Lin Z; Zhang X; Ye L
    J Biol Chem; 2012 Aug; 287(36):30228-39. PubMed ID: 22740693
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The oncoprotein HBXIP activates transcriptional coregulatory protein LMO4 via Sp1 to promote proliferation of breast cancer cells.
    Yue L; Li L; Liu F; Hu N; Zhang W; Bai X; Li Y; Zhang Y; Fu L; Zhang X; Ye L
    Carcinogenesis; 2013 Apr; 34(4):927-35. PubMed ID: 23291272
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The oncoprotein HBXIP upregulates PDGFB via activating transcription factor Sp1 to promote the proliferation of breast cancer cells.
    Zhang Y; Zhao Y; Li L; Shen Y; Cai X; Zhang X; Ye L
    Biochem Biophys Res Commun; 2013 May; 434(2):305-10. PubMed ID: 23537647
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Deacetylation of tumor-suppressor MST1 in Hippo pathway induces its degradation through HBXIP-elevated HDAC6 in promotion of breast cancer growth.
    Li L; Fang R; Liu B; Shi H; Wang Y; Zhang W; Zhang X; Ye L
    Oncogene; 2016 Aug; 35(31):4048-57. PubMed ID: 26657153
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Essential role of METTL3-mediated m
    Visvanathan A; Patil V; Arora A; Hegde AS; Arivazhagan A; Santosh V; Somasundaram K
    Oncogene; 2018 Jan; 37(4):522-533. PubMed ID: 28991227
    [TBL] [Abstract][Full Text] [Related]  

  • 20. METTL3 depletion contributes to tumour progression and drug resistance via N6 methyladenosine-dependent mechanism in HR+HER2-breast cancer.
    Ouyang D; Hong T; Fu M; Li Y; Zeng L; Chen Q; He H; Wen Y; Cheng Y; Zhou M; Zou Q; Yi W
    Breast Cancer Res; 2023 Feb; 25(1):19. PubMed ID: 36765397
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 55.